About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Multiple Sclerosis Clinical Trials in Philadelphia | 137 Studies

Clinical Trials Multiple SclerosisPhiladelphia

Multiple Sclerosis Clinical Trials in Philadelphia

Find 137 clinical trials for multiple sclerosis near Philadelphia, Pennsylvania. Connect with research centers in your area.

All Multiple Sclerosis trials nationwide All trials in Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 41-60 of 137 trials

CompletedA Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS).NCT02634307·Cullman, Alabama and 114 others

Multiple Sclerosis Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix San Antonio

Data from ClinicalTrials.govTerms

TerminatedA Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as…NCT00642902·Phoenix, Arizona and 49 others

CompletedNatalizumab High Titer Immunogenicity and SafetyThe primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E)…NCT00516893·Washington D.C., District of Columbia and 12 others

Active not recruitingPharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of OfatumumabThis study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by…NCT06869785·Birmingham, Alabama and 62 others

UnknownA Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple SclerosisThis is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal…NCT00217295·Philadelphia, Pennsylvania

TerminatedCOVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersThis is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with…NCT05000216·Los Angeles, California and 28 others

Enrolling by invitationImmune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct CannulationIn this study, lymph fluid will be collected by cannulation of the thoracic duct, a minimally invasive procedure performed by interventional radiologists.NCT05162638·Philadelphia, Pennsylvania

CompletedDiscontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new Magnetic Resonance Imaging (MRI) changes diminish significantly as people age…NCT03073603·Los Angeles, California and 18 others

CompletedCombination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxThis is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either…NCT00211887·Birmingham, Alabama and 70 others

CompletedAn Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MSThe purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex.NCT00206648·Tucson, Arizona and 52 others

UnknownClosed Kinetic Chain Exercises for Balance and Gait Rehabilitation for People With MSIn total, 27 patients with MS (Expanded Disability Status Scale (EDSS) score equal to or less than 5.5) were randomly assigned to either Telko plus conventional physical therapy…NCT05460299·Amman

CompletedSafety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple SclerosisThe objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in participants with…NCT01324232·Cullman, Alabama and 71 others

CompletedRelapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in…NCT04410991·Cullman, Alabama and 185 others

TerminatedOpen Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple SclerosisThe purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.NCT00595920·Cullman, Alabama and 26 others

Active not recruitingObesity and Pediatric Multiple SclerosisObesity is one possible contributor to severity of multiple sclerosis and progression of the disease.NCT04593082·Philadelphia, Pennsylvania and 1 other

CompletedStudy of Fampridine-ER Tablets in Patients With Multiple SclerosisThe purpose of this study is to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets compared to the currently approved dose in improving…NCT01328379·Cullman, Alabama and 69 others

CompletedSafety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentThis study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.NCT03436199·Cullman, Alabama and 83 others

CompletedNatalizumab Re-Initiation of DosingThe primary objectives of this study are to further evaluate the safety of natalizumab (Tysabri®) monotherapy by evaluating the risk of hypersensitivity and immunogenicity…NCT00306592·Birmingham, Alabama and 62 others

CompletedLong-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment…NCT03961204·Atlanta, Georgia and 98 others

RecruitingTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOThis phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum…NCT03816345·Birmingham, Alabama and 51 others

PreviousPage 3 of 7Next

Other Conditions in Philadelphia

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia